GlassScriptPhysician profile
Roderick Nisi
NPI 1821179714
$4,908.50
in general payments reported to CMS, 2019-2025
35 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $148 · 2021: $157 · 2022: $542 · 2023: $850 · 2024: $1,114 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390 · Education: $87.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.21 |
| Education | $87.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.20 | 2019-2025 | |
| Janssen Biotech, INC. | $651.28 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $371.75 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $229.03 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $223.32 | 2020-2025 | |
| Pfizer INC. | $185.90 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.45 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $159.56 | 2024-2025 | Voquezna |
| Vivus LLC | $153.04 | 2022-2025 | Pancreaze |
| Lilly USA, LLC | $132.48 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $114.45 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $112.28 | 2019-2024 | Dificid |
| Qol Medical, LLC | $98.21 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $85.65 | 2022-2024 | Dupixent |
| Daiichi Sankyo INC. | $83.03 | 2019-2023 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $59.30 | 2019-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $57.11 | 2022-2023 | |
| Braintree Laboratories, INC. | $53.25 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $46.87 | 2024-2025 | Vowst |
| Intercept Pharmaceuticals, INC. | $42.70 | 2019 | |
| Ucb, INC. | $40.77 | 2019 | |
| Medtronic, INC. | $39.56 | 2022 | |
| Allergan, INC. | $32.84 | 2019-2020 | |
| Exact Sciences Corporation | $32.83 | 2023-2024 | Cologuard Collection Kit |
| Tersera Therapeutics LLC | $30.57 | 2024 | Xermelo |
| Genzyme Corporation | $25.51 | 2022 | |
| Ferring Pharmaceuticals INC. | $24.82 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $23.61 | 2025 | Rezdiffra |
| Shire North American Group INC | $23.04 | 2019 | |
| Boston Scientific Corporation | $20.71 | 2019 | |
| Capsovision, INC. | $18.39 | 2025 | Capsocam Plus |
| Echosens North America, INC. | $16.48 | 2024 | Fibroscan |
| Ipsen Biopharmaceuticals, INC | $14.98 | 2025 | Iqirvo |
| Cook Medical LLC | $14.05 | 2025 | Echotip Insight |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Nisi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.